News

According to the Medidata, Balance allows study teams to reduce trial planning and implementation time, effort and costs and the number of subjects required to be enrolled. The

CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. CTI is in the process of preparing a

The study is expected to evaluate the efficacy, safety and tolerability of Cogane, administered for 28 weeks to patients with early stage Parkinson’s disease. The primary endpoint for

Protonix inhibits gastric acid secretion and is prescribed for the short-term treatment of conditions such as stomach ulcers associated with gastroesophageal reflux disease as well as the long

Lyrica was approved in Japan on April 16, 2010 and was listed in the NHI drug price list. Pfizer Japan and Eisai are jointly promoting sale of the

In the notice letter, Lupin alleges that all 10 patents associated with Ranexa are invalid, unenforceable and/or will not be infringed by Lupin’s manufacture, use or sale of

NexMed management has been advised that Health Canada is continuing to review its response for acceptance, and the company expects to hear from the agency within the next

Cardium is expecting to initiate Generx clinical study in the second half of this year. The trial is expected to be a randomised, controlled, parallel-group, multicenter study to

Bristol-Myers Squibb and Pfizer said that the Averroes study is expected to be stopped early because a predefined interim analysis by an independent Data Monitoring Committee (DMC) showed